Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700532 | 1.00 | KMT2A (0.47) | KMT2AL3MBTL1AKT1SCN9AGAA | |
| SCHEMBL4816939 | 0.90 | SCN9A (0.48) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL4817994 | 0.90 | SCN9A (0.48) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL24379309 | 0.90 | SCN9A (0.48) | KMT2AL3MBTL1SCN9A | |
| SCHEMBL7420003 | 0.87 | SCN9A (0.47) | KMT2AL3MBTL1SCN9ACA12CA1 | |
| SCHEMBL19135097 | 0.82 | KMT2A (0.47) | KMT2AL3MBTL1AKT1SCN9ACTSL | |
| SCHEMBL7723389 | 0.82 | KMT2A (0.47) | KMT2AL3MBTL1AKT1SCN9ACTSL | |
| SCHEMBL26317923 | 0.82 | KMT2A (0.45) | KMT2AL3MBTL1GAACTSLSYK | |
| SCHEMBL29048164 | 0.81 | SMN1; SMN2 (0.57) | KMT2AL3MBTL1SCN9AGAA | |
| SCHEMBL9655226 | 0.81 | KMT2A (0.48) | KMT2AL3MBTL1AKT1SCN9ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | KMT2A 2085/4885L3MBTL1 3869/4885AKT1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.